We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with uncontrolled gout had additional burdens ...

BLOOM (TAMPA) – Nephrologist Jason B. Rothschild, MD, recently joined Gayle Guyardo, the host of the globally syndicated health and wellness show Bloom, to discuss the often-overlooked connection ...

Sorry, but your browser does not support the video tag. (BPT) – At 21 years old, Khashayar (Khash) B. lived a life similar to any other young adult. He spent time ...

Patients with gout are more likely than those without to initiate chronic opioid use. Patients with gout are more likely than those without to initiate chronic opioid use, according to study results ...

The MarketWatch News Department was not involved in the creation of this content. -- Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients ...

At least 9 million Americans are said to experience this discomfort—and experts say suffering through it is, in part, due to ...

Some advice was okay to an extent. Others were clearly a money grab.

Veterans with gout were 30% more likely to be prescribed chronic opioid therapy than those without gout, with factors such as female sex, underweight BMI, current smoking status, and a higher burden ...

Xanthine oxidase inhibitors, primarily allopurinol and febuxostat, are the mainstay of treatment. The goal of chronic gout management includes lowering serum urate levels to below 6 mg/dL. 5 Overall, ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic ...

Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients with mild to moderate renal impairment, showed the URAT1 inhibitor lowered serum uric ...